These trials have targeted various groups, including individuals with diabetes, focusing on cognitive effects, and those with or at risk of AD or PD (summarized in Table 2 for AD and Table 3 for PD)
Clinical implication Clinicians are encouraged to perform comprehensive evaluations prior to prescribing GLP-1 RA therapy in patients with a history of pancreatic disorders or other pancreatitis risk factors
Back Flint, A, Raben, A, Astrup, A, Holst, JJ (1 Feb 1998) 'Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans', The Journal of Clinical Investigation , 101/3, 515-20
& Wang, Y
However, he says, These symptoms could have come from a GI bug going around. But P.B
Secondary end points included change from baseline in fasting plasma glucose (FPG), postprandial glucose ( PPG) and body weight